{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T23:01:38Z","timestamp":1781218898756,"version":"3.54.1"},"reference-count":28,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"unspecified","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"crossref","award":["NIHR130580"],"award-info":[{"award-number":["NIHR130580"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Institute for Health"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2025,1,7]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To develop and validate a prognostic model for risk-stratified monitoring of 5-aminosalicylate nephrotoxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This UK retrospective cohort study used data from the Clinical Practice Research Datalink Aurum and Gold for model development and validation respectively. It included adults newly diagnosed with inflammatory bowel disease and established on 5-aminosalicylic acid (5-ASA) treatment between 1 January 2007 and 31 December 2019. Drug discontinuation associated with 5-ASA nephrotoxicity defined as a prescription gap of \u226590 days with decline in kidney function was the outcome. Patients prescribed 5-ASAs for \u22656 months were followed-up for up to 5 years. Penalised Cox regression was used to develop the risk equation with bootstrapping for internal validation and optimism adjustment. Model performance was assessed in terms of calibration and discrimination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>13\u2009728 and 7318 participants who contributed 40\u2009378 and 20\u2009679 person-years follow-up formed the development and validation cohorts with 170 (1.2%) and 98 (1.3%) outcome events respectively. Nine predictors were included in the final model, including chronic kidney disease stage 3 and hazardous alcohol use as strong predictors. Age and Body Mass Index were weak predictors. The optimism-adjusted calibration slope, C and D statistics in the development and validation data were 0.90, 0.64 and 0.98, and 1.01, 0.66 and 0.94 respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This prognostic model used information from routine clinical care and performed well in an independent validation cohort. It can be used to risk-stratify blood test monitoring during established 5-ASA treatment. A key limitation is that the decline in kidney function could have been due to factors other than 5-ASA nephrotoxicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjgast-2024-001627","type":"journal-article","created":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T06:35:15Z","timestamp":1737786915000},"page":"e001627","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Monitoring for 5-aminosalicylate nephrotoxicity in adults with inflammatory bowel disease: prognostic model development and validation using data from the Clinical Practice Research Datalink"],"prefix":"10.1136","volume":"12","author":[{"given":"Abhishek","family":"Abhishek","sequence":"first","affiliation":[{"name":"Academic Rheumatology, University of Nottingham, Nottingham, East Midlands, UK"},{"name":"Nottingham NIHR BRC, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3859-7354","authenticated-orcid":false,"given":"Georgina","family":"Nakafero","sequence":"additional","affiliation":[{"name":"Academic Rheumatology, University of Nottingham, Nottingham, East Midlands, UK"},{"name":"Nottingham NIHR BRC, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2555-2250","authenticated-orcid":false,"given":"Tim","family":"Card","sequence":"additional","affiliation":[{"name":"Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten W","family":"Taal","sequence":"additional","affiliation":[{"name":"Centre for Kidney Research and Innovation, Translational Medical Sciences, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J","family":"Grainge","sequence":"additional","affiliation":[{"name":"Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guruprasad P","family":"Aithal","sequence":"additional","affiliation":[{"name":"Nottingham NIHR BRC, Nottingham, UK"},{"name":"Nottingham Digestive Diseases Centre, Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian D","family":"Mallen","sequence":"additional","affiliation":[{"name":"Primary Care Centre Versus Arthritis, Keele University, Keele, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D","family":"Stevenson","sequence":"additional","affiliation":[{"name":"School of Health and Related Research, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D","family":"Riley","sequence":"additional","affiliation":[{"name":"Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK"},{"name":"NIHR, Birmingham Biomedical Research Centre, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,1,25]]},"reference":[{"key":"2026010701051094000_12.1.e001627.1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318484"},{"key":"2026010701051094000_12.1.e001627.2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.12.009"},{"key":"2026010701051094000_12.1.e001627.3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.crohns.2009.12.002","article-title":"The second European evidence-based Consensus on the diagnosis and management of Crohn\u2019s disease: Current management","volume":"4","author":"Dignass","year":"2010","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"2026010701051094000_12.1.e001627.4","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.03.016"},{"key":"2026010701051094000_12.1.e001627.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02462.x"},{"key":"2026010701051094000_12.1.e001627.6","doi-asserted-by":"crossref","DOI":"10.1186\/s40001-022-00687-y","article-title":"5-ASA induced interstitial nephritis in patients with inflammatory bowel disease: a systematic review","volume":"27","author":"Moss","year":"2022","journal-title":"Eur J Med Res"},{"key":"2026010701051094000_12.1.e001627.7","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv219"},{"key":"2026010701051094000_12.1.e001627.8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2036.2000.00683.x","article-title":"Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease","volume":"14","author":"Corrigan","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"2026010701051094000_12.1.e001627.9","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20099"},{"key":"2026010701051094000_12.1.e001627.10","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.ndt.a027349"},{"key":"2026010701051094000_12.1.e001627.11","unstructured":"Committee JF . British national formulary (85). London: BMJ Group and Pharmaceutical Press, 2023."},{"key":"2026010701051094000_12.1.e001627.12","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.dld.2021.11.008","article-title":"Kidney function monitoring in inflammatory bowel disease: The MONITORED consensus","volume":"54","author":"Guillo","year":"2022","journal-title":"Dig Liver Dis"},{"key":"2026010701051094000_12.1.e001627.13","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2014-100452"},{"key":"2026010701051094000_12.1.e001627.14","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyv098"},{"key":"2026010701051094000_12.1.e001627.15","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyz034"},{"key":"2026010701051094000_12.1.e001627.16","doi-asserted-by":"publisher","DOI":"10.1159\/000339789"},{"key":"2026010701051094000_12.1.e001627.17","doi-asserted-by":"publisher","DOI":"10.1038\/kisup.2013.79"},{"key":"2026010701051094000_12.1.e001627.18","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/apt.15408","article-title":"No increased risk of nephrotoxicity associated with 5-aminosalicylic acid in IBD: a population-based cohort and nested case-control study","volume":"50","author":"Jairath","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2026010701051094000_12.1.e001627.19","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1155\/2009\/501345","article-title":"Renal effects of long-term treatment with 5-aminosalicylic acid","volume":"23","author":"Patel","year":"2009","journal-title":"Can J Gastroenterol"},{"key":"2026010701051094000_12.1.e001627.20","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.10.1530"},{"key":"2026010701051094000_12.1.e001627.21","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.m441","article-title":"Calculating the sample size required for developing a clinical prediction model","volume":"368","author":"Riley","year":"2020","journal-title":"BMJ"},{"key":"2026010701051094000_12.1.e001627.22","doi-asserted-by":"publisher","DOI":"10.1177\/096228029900800102"},{"key":"2026010701051094000_12.1.e001627.23","doi-asserted-by":"crossref","unstructured":"Steyerberg EW . Clinical prediction models: a practical approach to development, validation, and updating. Cham, Switzerland: Springer International Publishing AG, 2019.","DOI":"10.1007\/978-3-030-16399-0"},{"key":"2026010701051094000_12.1.e001627.24","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-13-33","article-title":"External validation of a Cox prognostic model: principles and methods","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med Res Methodol"},{"key":"2026010701051094000_12.1.e001627.25","doi-asserted-by":"publisher","DOI":"10.2307\/2281704"},{"key":"2026010701051094000_12.1.e001627.26","doi-asserted-by":"publisher","DOI":"10.7326\/M14-0698"},{"key":"2026010701051094000_12.1.e001627.27","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/apt.14323","article-title":"Risk factors for thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype","volume":"46","author":"Broekman","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2026010701051094000_12.1.e001627.28","first-page":"404","article-title":"Toxicity profile of thiopurines in inflammatory bowel disease: a retrospective cohort analysis","volume":"98","author":"Labidi","year":"2020","journal-title":"Tunis Med"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2024-001627","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T09:05:26Z","timestamp":1767776726000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2024-001627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,25]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/bmjgast-2024-001627"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2024-001627","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}